EP Patent

EP1307486A2 — Somatostatin analogues

Assigned to Novartis Pharma GmbH · Expires 2003-05-07 · 23y expired

What this patent protects

The invention provides cyclo[{4-(NH2-C2H4-NH-CO-O-)Pro}-Phg-DTrp-Lys-Tyr(4-Benzyl)-Phe], optionally in protected form, or a pharmaceutically acceptable salt or complex thereof, which has interesting pharmaceutical properties.

USPTO Abstract

The invention provides cyclo[{4-(NH2-C2H4-NH-CO-O-)Pro}-Phg-DTrp-Lys-Tyr(4-Benzyl)-Phe], optionally in protected form, or a pharmaceutically acceptable salt or complex thereof, which has interesting pharmaceutical properties.

Drugs covered by this patent

Patent Metadata

Patent number
EP1307486A2
Jurisdiction
EP
Classification
—
Expires
2003-05-07
Drug substance claim
No
Drug product claim
No
Assignee
Novartis Pharma GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.